Strides gets USFDA nod for anti-allergic drug

The company said, it is focusing on building a private label business in the US by leveraging its portfolio of products across softgels, tablets, capsules and other proprietary formats.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30pohUY
via IFTTT